Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy


      Objective. Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy.
      Material. The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton® Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 μg).
      Results. Following the Se supplementation in a daily dose of 200 μg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-Px in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation.
      An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001).
      After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated.
      Conclusion. As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pilawski Z.
        • Kośmider M.
        • Kozłowski D.
        Cisplatin and adriamycin in the treatment of non-operable ovarian tumors. The first scientific meeting of obstetricians and gynecologists in Poznań, Heliodor ŚwiMath Eqcicki Days”, Poznań 25-30.05.
        Pol. Gynecol. (Polish). 1987; 58: 98-201
        • Shallon J.
        • Juvekar A.
        • Chitnis M.
        Selenium (Se) cytotoxicity in drug sensitive and drug resistant murine tumor.
        Cancer Biother. 1995; 10: 243-248
        • Baldew G.S.
        • van den Hamer C.J.
        • Los G.
        • Vermeulen N.P.
        • de Goeij J.J.
        • McVie J.G.
        Selenium-induced protection against cis-diaminedichloroplatinum (II) nephrotoxicity in mice and rats.
        Cancer Res. 1989; 49: 3020-3023
        • Sieja K.
        Selenium (Se) deficiency in women with ovarian cancer undergoing chemotherapy and the influence of supplementation with this microelement on biochemical parameters.
        Pharmazie. 1998; 53: 473-476
        • Vernie L.N.
        • de-Goeij J.J.
        • Zegres C.
        • de-Vries M.
        • Baldew G.S.
        • McVie J.G.
        Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients.
        Cancer Lett. 1987; 40: 89-91
        • Young V.R.
        Selenium a case for its essentiality in man.
        N. Engl. J. Med. 1981; 304: 1228-1230
        • Lachowicz L.
        Cisplatin adverse reactions in patients with cancer.
        Pol. Med. J. (Polish). 1989; 64: 25-26
        • Roszkowski K.
        • Piekutowski K.
        Free radicals. Defense activity of antioxidant vitamins in prevention and treatment of cancers.
        Contemp. Oncol. (Polish). 1999; 4: 143-144
        • Burk R.F.
        • Foster K.A.
        • Greenfield P.M.
        • Kiker K.W.
        • Hammon J.P.
        Binding of simultaneously administered inorganic selenium and mercury to a rat plasma protein.
        Proc. Soc. Exp. Med. 1974; 144: 782-785
        • Comb Jr., G.F.
        • Clark L.C.
        • Turnbull B.M.
        An analysis of cancer prevention by selenium.
        Biofactors. 2001; 14: 153-159
        • Sheeehan T.M.
        • Halls D.J.
        Measurement of selenium in clinical specimens.
        Ann. Clin. Biochem. 1999; 36: 301-305
        • Fracescato H.D.
        • Costa R.S.
        • Rodrigues-Camargo S.M.
        • Zanetti M.A.
        • Lavrador M.A.
        • Bianchi M.D.
        Effect of oral selenium administration on cisplatin-induced nephrotoxicity in rats.
        Pharmacol. Res. 2001; 43: 77-82
        • Medcalf A.S.
        • Wade M.H.
        Comparison of mutagenicity of N-methyl-N-nitrosourea and N-ethyl-nitrosourea in human diploid fibroblasts.
        Carcinogenesis. 1983; 4: 115-118
        • Smith A.M.
        • Chang M.P.
        • Medeiros L.C.
        Generational differences in selenium status of women.
        Biol. Trace Elem. Res. 2000; 75: 157-165
        • Kanias G.D.
        • Kouri E.
        Biological evaluation of trace element data in human ovaries by statistical analysis.
        Biol. Trace Elem. Res. 1996; 52: 65-66
        • Behne D.
        • Gessner H.
        • Kyrialopoulos A.
        Information on the selenium status of several body compartments of rats from selenium concentrations in blood fractions, hair and nails.
        J. Trace Elem. Med. Biol. 1996; 10: 174-179
        • Beretta S.
        Cancer treatment medical guide.
        in: 10th ed. Farmitalia Carlo Erba-Erbamount, Milan1991: 68-83
        • Watkinson J.H.
        Fluorometric determination of selenium material with 2,3 diaminonaphtalene.
        Anal. Chem. 1966; 38: 92-97
        • Danch A.
        • Dróżdż M.
        Simplified fluorometric method for the determination of selenium in biological materials.
        Lab. Diagn. (Polish). 1996; 32: 524-529
        • Paglia D.E.
        • Valentine W.N.
        Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
        J. Lab. Clin. Med. 1967; 70: 158-168
        • Lawrence R.A.
        • Burk R.F.
        Glutathione peroxidase activity in selenium-deficient rat liver.
        Biochem. Biophys. Res. Commun. 1976; 71: 952-958
        • Okuma T.
        • Steiner N.
        • Baldini M.
        Studies on lipid peroxides in platelets. I. Method of assay and effect of storage.
        J. Lab. Clin. Med. 1970; 75: 283-290
        • Stuart M.J.
        • Murphy S.
        • Oski F.A.
        A simple nonradioisotope technique for the determination of platelet life span.
        N. Engl. J. Med. 1975; 292: 1301-1313
        • JarzMath Eqbek Z.
        • Naskalski J.W.
        Selenium—a new parameter in clinical laboratory.
        Lab. Diagn. (Polish). 1991; 29: 50-55
        • Dróżdż M.
        • Tomala J.
        • JMath Eqdryczko A.
        • Banas K.
        Concentration of selenium and vitamin E in the serum of women with malignant genital neoplasm's and their family members.
        Pol. Gynecol. (Polish). 1989; 60: 301-305
        • Das N.P.
        • Ma C.W.
        Serum selenium concentrations in ovarian cancer patients using a simplified fluometric procedure.
        Biol. Trace Elem. Res. 1986; : 215-218
        • Sundström H.
        • Korpela H.
        • Viinikka L.
        • Kauppuila A.
        Serum selenium and glutathione peroxidase and plasma lipid peroxides in uterine, ovarian, and vulvae cancer, and their responses to antioxidants in patients with ovarian cancer.
        Cancer Lett. 1984; 24: 1-10
        • Kośmider M.
        • Malecha J.
        • Szczypiński J.
        • Wydra E.
        • Sieja K.
        • Borowiak D.
        Importance of selenium in combined treatment of ovarian neoplasma.
        Pol. Gynecol. (Polish). 1991; 32: 529-534
        • Bednarek D.
        • Kondracki M.
        • Cakała S.
        Effect of selenium and vitamin E on white cells, serum concentration of several minerals and trace elements as well as immunological parameters in calves.
        Dtsch. Tierartl. Wochenschr. 1996; 103: 457-459
        • Hu Y.J.
        • Chen Y.
        • Zhang Y.Q.
        • Zhou M.Z.
        • Song X.M.
        • Zhang B.Z.
        • et al.
        The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
        Biol. Trace Elem. Res. 1997; 56: 331-341
        • Wanik A.
        • Wysocki J.
        • ChorMath Eqży M.
        The role of free radicals in human pathology.
        Pol. Med. J. (Polish). 1990; 45: 195-199
      1. Woźniak Z. The influence of selenium on the dynamics and growth morphology in transplantable kidney and breast cancers induced by aflatoxin in Wistar's rats—doctorial thesis—Medical Academy in Wrocław (Polish), Wrocław 1988:1–102.

        • Matsuda A.
        • Kimura A.
        • Itokawa Y.
        Influence of selenium o the acute cardiotoxicity of adriamycin in rats.
        Biol. Trace Elem. Res. 1997; 57: 157-167
        • Knudsen C.A.
        • Tappel A.L.
        • North J.A.
        Multiple antioxidants protection against hems protein and lipid oxidation in kidney tissue.
        Free Radic. Biol. Med. 1996; 20: 165-173
        • Kiremidijan-Schumacher L.
        • Roy M.
        • Wiske H.I.
        • Cohen M.W.
        • Slotzky G.
        Supplementation with selenium augments the function of natural killer and lymphokine-activated killer cells.
        Biol. Trace Elem. Res. 1996; 52: 227-239
        • Avtsyn A.P.
        • Zhanoronkov A.A.
        • Strochkova L.S.
        • Kornev A.V.
        Effect of sodium selenite on tumor cells in culture.
        Vopr. Onkol. (Mosk.). 1986; 32: 77-80
        • Babenko G.A.
        • Pogribny T.P.
        • Maskakevich J.J.
        Effect of sodium selenite on the activity of antioxidant enzymes (superoxide dismutase, glutathione peroxidase) during hepatocarcinogenesis.
        Eksp. Onkol. (Mosk.). 1986; 8: 31-33
        • Xue F.X.
        • Zhang S.W.
        Selenium concentrations in serum, hair and tumor tissue from patients with ovarian tumors.
        Chun-Hua-Fu-Chan-Ko-Tsa-Chih. 1991; 26: 290-295
        • Vadgama J.V.
        • Wu Y.
        • Shen D.
        • Hsia S.
        • Block J.
        Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
        Anticancer Res. 2000; 20: 1391-1414